Paul A. BUNN,Christopher D. COLDREN,Wilbur A. FRANKLIN,Mark W. GERACI,Barbara A. HELFRICH,Fred R. HIRSCH,Razvan LAPADAT,Michio SUGITA,Samir E. WITTA
申请号：
US13418004
公开号：
US20120177641A1
申请日:
2012.03.12
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
